<DOC>
	<DOCNO>NCT02022280</DOCNO>
	<brief_summary>In randomize control crossover study , investigator propose test hypothesis proton pump inhibitor ( PPIs ) increase plasma level asymmetric dimethylarginine ( ADMA ) , marker endothelial dysfunction . The author propose evaluate ADMA concentration vascular function analysis healthy volunteer adult history cardiovascular disease give PPI v placebo four week .</brief_summary>
	<brief_title>Effect Proton Pump Inhibitors Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Healthy male female volunteer age 18 75 year ( n=10 ) male female volunteer history coronary peripheral artery disease ( n=10 ) Able understand nature study give write informed consent Able communicate well investigator his/her representative Body Mass Index 18 kg/m^2 35 kg/m^2 screen visit Creatinine &lt; 1.5 , liver enzymes &lt; 2x normal , laboratory test consider normal significant clinical relevance study investigator Contraindication proton pump inhibitor treatment Current treatment PPI H2 antagonist , able tolerate withdrawal washout medication . Current historical evidence clinically severe cardiovascular , neurological , hematological , hepatic , gastrointestinal , renal , pulmonary , endocrinological , metabolic psychiatric disease . Any acute chronic disease could influence volunteer 's health and/or study result Presence history malabsorption gastrointestinal surgery except appendectomy hernia repair Use enzyme inducer enzyme inhibitor drug within last three month first drug administration Participation another ongoing clinical trial Past current drug exposure amount drug abuse addiction Past current alcohol exposure amount alcohol abuse addiction ( i.e . &gt; 28 unit per week male , 1 unit = one measure spirit ( 25 mL ) , one glass wine ( 125 mL ) 1/2 pint beer ) Donation blood major blood loss ( &gt; 500 mL ) within three month study Unwilling unable comply study protocol reason opinion investigator participate study Positive test hepatitis B surface antigen , hepatitis C antibody , HIV1 HIV2 antibody screen Known allergy intolerance compound study drug closely relate compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>